参考文献/References:
[1] Sekulic' V,Rajic' M,Vlajkovic' M,et al.The effect of short-term treatment with lithium carbonate on the outcome of radioiodine therapy in patients with long-lasting Graves' hyperthyroidism[J].Ann Nucl Med,2017,31(10):744-751.DOI:10.1007/s12149-017-1206-z.
[2] ukawska E,Frankiewicz D,Izak M,et al.Lithium toxicity and the kidney with special focus on nephrotic syndrome associated with the acute kidney injury:a case-based systematic analysis[J].J Appl Toxicol,2021,41(12):1896-1909.DOI:10.1002/jat.4167.
[3] Peri A,Giuliani C.Management of euvolemic hyponatremia attributed to SIADH in the hospital setting[J].Minerva Endocrinol,2014,39(1):33-41.DOI:10.1007/s10545-014-9692-9.
[4] McKnight RF,Adida M,Budge K,et al.Lithium toxicity profile:a systematic review and meta-analysis[J].Lancet,2012,379(9817):721-728.DOI:10.1016/S0140-6736(11)61516-X.
[5] Kavanagh C,Uy NS.Nephrogenic diabetes insipidus[J].Pediatr Clin North Am,2019,66(1):227-234.DOI:10.1016/j.pcl.2018.09.006.
[6] 张纾,林强,孙立伟,等.652例碳酸锂不良反应报告分析[J].中国药物警戒,2018,15(4):234-239.DOI:10.3969/j.issn.1672-8629.2018.04.010.
[7] Ossani GP,Uceda AM,Acosta JM,et al.Role of oxidative stress in lithium-induced nephropathy[J].Biol Trace Elem Res,2019,191(2):412-418.DOI:10.1007/s12011-018-1617-2.
[8] Thomas L,Xue J,Dominguez Rieg JA,et al.Contribution of NHE3 and dietary phosphate to lithium pharmacokinetics[J].Eur J Pharm Sci,2019,128:1-7.DOI:10.1016/j.ejps.2018.11.008.
[9] Kortenoeven ML,Schweer H,Cox R,et al.Lithium reduces aquaporin-2 transcription independent of prostaglandins[J].Am J Physiol Cell Physiol,2012,302(1):C131-140.DOI:10.1152/ajpcell.00197.2011.
[10] Christensen BM,Kim YH,Kwon TH,et al.Lithium treatment induces a marked proliferation of primarily principal cells in rat kidney inner medullary collecting duct[J].Am J Physiol Renal Physiol,2006,291(1):F39-48.DOI:10.1152/ajprenal.00383.2005.
[11] de Groot T,Alsady M,Jaklofsky M,et al.Lithium causes G2 arrest of renal principal cells[J].J Am Soc Nephrol,2014,25(3):501-510.DOI:10.1681/ASN.2013090988.
[12] Ommati MM,Niknahad H,Farshad O,et al.In vitro and in vivo evidence on the role of mitochondrial impairment as a mechanism of lithium-induced nephrotoxicity[J].Biol Trace Elem Res,2021,199(5):1908-1918.DOI:10.1007/s12011-020-02302-9.
[13] Kalita-De Croft P,Bedford JJ,Leader JP,et al.Amiloride modifies the progression of lithium-induced renal interstitial fibrosis[J].Nephrology(Carlton),2018,23(1):20-30.DOI:10.1111/nep.12929.
[14] Kim GH,Lee JW,Oh YK,et al.Antidiuretic effect of hydrochlorothiazide in lithium-induced nephrogenic diabetes insipidus is associated with upregulation of aquaporin-2,Na-Cl co-transporter,and epithelial sodium channel[J].J Am Soc Nephrol,2004,15(11):2836-2843.DOI:10.1097/01.ASN.0000143476.93376.04.
[15] Allen HM,Jackson RL,Winchester MD,et al.Indomethacin in the treatment of lithium-induced nephrogenic diabetes insipidus[J].Arch Intern Med,1989,149(5):1123-1126.DOI:10.1001/archinte.150.11.2420b.
[16] Zhang Y,Peti-Peterdi J,Muller CE,et al.P2Y12 receptor localizes in the renal collecting duct and its blockade augments arginine vasopressin action and alleviates nephrogenic diabetes insipidus[J].J Am Soc Nephrol,2015,26(12):2978-2987.DOI:10.1681/ASN.2014010118.
[17] Sanches TR,Volpini RA,Massola Shimizu MH,et al.Sildenafil reduces polyuria in rats with lithium-induced NDI[J].Am J Physiol Renal Physiol,2012,302(1):F216-225.DOI:10.1152/ajprenal.00439.2010.
[18] Cheung PW,Nomura N,Nair AV,et al.EGF receptor inhibition by erlotinib increases aquaporin 2-mediated renal water reabsorption[J].J Am Soc Nephrol,2016,27(10):3105-3116.DOI:10.1681/ASN.2015080903.
[19] Schoot TS,Molmans THJ,Grootens KP,et al.Systematic review and practical guideline for the prevention and management of the renal side effects of lithium therapy[J].Eur Neuropsychopharmacol,2020,31:16-32.DOI:10.1016/j.euroneuro.2019.11.006.
[20] Fotso Soh J,Torres-Platas SG,Beaulieu S,et al.Atorvastatin in the treatment of Lithium-induced nephrogenic diabetes insipidus:the protocol of a randomized controlled trial[J].BMC Psychiatry,2018,18(1):227.DOI:10.1186/s12888-018-1793-9.
[21] Klein JD,Wang Y,Blount MA,et al.Metformin,an AMPK activator,stimulates the phosphorylation of aquaporin 2 and urea transporter A1 in inner medullary collecting ducts[J].Am J Physiol Renal Physiol,2016,310(10):F1008-1012.DOI:10.1152/ajprenal.00102.2016.
[22] Tas HI,Sancak EB.Protective effect of metformin on lithium-induced nephrogenic diabetes insipidus:an experimental study in rats[J].Adv Clin Exp Med,2021,30(11):1185-1193.DOI:10.17219/acem/140403.
相似文献/References:
[1]朱丹,陈国芳,刘超,等.糖尿病患者合并甲状腺功能异常的机制
及其影响[J].国际内分泌代谢杂志,2016,36(03):206.[doi:10.3760/cma.j.issn.1673-4157.2016.03.16]
Zhu Dan*,Chen Guofang,Liu Chao,et al.Mechanisms of diabetes combined with thyroid dysfunction and its influence[J].International Journal of Endocrinology and Metabolism,2016,36(06):206.[doi:10.3760/cma.j.issn.1673-4157.2016.03.16]
[2]韩煦,魏军平.促甲状腺激素受体抗体的检测及其在Graves病
诊疗中的价值[J].国际内分泌代谢杂志,2017,37(02):94.[doi:10.3760/cma.j.issn.1673-4157.2017.02.006]
Han Xu,Wei Junping..Thyroid stimulating hormone receptor antibodies assays and its clinical significance in Graves' disease[J].International Journal of Endocrinology and Metabolism,2017,37(06):94.[doi:10.3760/cma.j.issn.1673-4157.2017.02.006]
[3]朱萍,卫红艳,王坤玲,等.Graves病甲状腺功能亢进症性肝损害的
相关因素分析[J].国际内分泌代谢杂志,2017,37(03):164.[doi:10.3760/cma.j.issn.1673-4157.2017.03.005]
Zhu Ping,Wei Hongyan,Wang Kunling,et al.Related factors of hyperthyroidism-related liver dysfunction in Graves' disease[J].International Journal of Endocrinology and Metabolism,2017,37(06):164.[doi:10.3760/cma.j.issn.1673-4157.2017.03.005]
[4]郑仁东,刘超.碳酸锂与内分泌功能紊乱[J].国际内分泌代谢杂志,2017,37(03):186.[doi:10.3760/cma.j.issn.1673-4157.2017.03.011]
Zheng Rendong,Liu Chao..Lithium and endocrine disturbances[J].International Journal of Endocrinology and Metabolism,2017,37(06):186.[doi:10.3760/cma.j.issn.1673-4157.2017.03.011]
[5]刘燕晶 张帆.甲状腺功能亢进症性肝损害的发生机制[J].国际内分泌代谢杂志,2019,39(01):34.[doi:10.3760/cma.j.issn.1673-4157.2019.01.008]
Liu Yanjing,Zhang Fan.The pathogenesis of liver damage of hyperthyroidism[J].International Journal of Endocrinology and Metabolism,2019,39(06):34.[doi:10.3760/cma.j.issn.1673-4157.2019.01.008]
[6]姚瑶,郑仁东,刘超.血浆置换治疗甲状腺功能亢进症的研究进展[J].国际内分泌代谢杂志,2020,40(05):320.[doi:10.3760/cma.j.cn121383-20191218-12047]
Yao Yao,Zheng Rendong,Liu Chao.Update on plasmapheresis for hyperthyroidism[J].International Journal of Endocrinology and Metabolism,2020,40(06):320.[doi:10.3760/cma.j.cn121383-20191218-12047]
[7]刘天琪,张秀英,纪立农.促甲状腺激素受体抗体的检测及应用进展[J].国际内分泌代谢杂志,2021,41(01):5.[doi:10.3760/cma.j.cn121383-20200608-06021]
Liu Tianqi,Zhang Xiuying,Ji Linong..Progression of assay and clinical practice of thyroid stimulating hormone receptor antibody[J].International Journal of Endocrinology and Metabolism,2021,41(06):5.[doi:10.3760/cma.j.cn121383-20200608-06021]